{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:24:27Z","timestamp":1781108667768,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Als Bundesland mit dem h\u00f6chsten Altersdurchschnitt in Deutschland und besonderen Strukturmerkmalen l\u00e4ndlich gepr\u00e4gter Gebiete sind die Folgen des demographischen Wandels bereits heute in Sachsen sp\u00fcrbar. Um die medizinische Versorgung von Parkinson-Patienten zu verbessern, bedarf es einer Status-quo-Analyse der aktuellen Versorgungspraxis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel der Arbeit (Fragestellung)<\/jats:title>\n                <jats:p>Inwieweit unterscheidet sich die Inanspruchnahme der medizinischen Leistungserbringung von Parkinson-Patienten im Vergleich von st\u00e4dtisch und l\u00e4ndlich gepr\u00e4gten Gebieten sowie im Vergleich von Parkinson-Patienten mit und ohne Neurologenkontakt im Beobachtungszeitraum von 2011 bis 2019?<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Die Kohortenstudie basiert auf umfangreichen Routinedaten der Krankenkasse AOK PLUS der Jahre 2010 bis 2019 f\u00fcr Sachsen. Untersucht wurde eine Kohorte von insgesamt 15.744 Parkinson-Patienten (<jats:italic>n<\/jats:italic>\u202f=\u200967.448 Patientenjahre) und eine gematchte Vergleichskohorte (<jats:italic>n<\/jats:italic>\u202f=\u2009674.480 Patientenjahre; Kriterien: Geburtsjahr, Geschlecht, Versicherungsjahr, Wohnsitz Stadt\/Land) ohne ICD-10-Kodierung einer Bewegungsst\u00f6rung.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Insgesamt war eine kontinuierliche Zunahme der Anzahl der Erkrankten in der dynamischen Kohorte von 2011 (<jats:italic>n<\/jats:italic>\u202f=\u20096829) bis 2019 (<jats:italic>n<\/jats:italic>\u202f=\u20098254) zu beobachten. Stadt-Land-Unterschiede zeigten sich insbesondere in der geringeren (Mit\u2011)Behandlung durch niedergelassene Neurologen in l\u00e4ndlich gepr\u00e4gten Gebieten. Parkinson-Patienten hatten ein 3,5- bzw. 4\u2011fach erh\u00f6htes Risiko zu versterben im Vergleich zu Versicherten der Vergleichskohorte. Ver\u00e4nderungen der medikament\u00f6sen Parkinson-Therapie (Zunahme COMT- und MAO-Inhibitoren) sowie der Heilmittelerbringung (Zunahme Ergotherapie und Logop\u00e4die) \u00fcber die Beobachtungszeit zeigten sich prim\u00e4r bei Parkinson-Patienten mit Neurologenkontakt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>In der Studie konnten eine erh\u00f6hte Morbidit\u00e4t und Mortalit\u00e4t bei Parkinson-Patienten identifiziert werden, die sich als Ziel f\u00fcr innovative Versorgungskonzepte eignen. Die zunehmende Zahl an Patienten und die beschriebenen Unterschiede dokumentieren hierf\u00fcr den Bedarf. Gleichzeitig zeigen die Ver\u00e4nderungen in der Verordnungspraxis, dass innovative Therapien von niedergelassenen Neurologen eingesetzt werden.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00115-022-01273-7","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T17:19:15Z","timestamp":1647278355000},"page":"1206-1218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Versorgungssituation von Parkinson-Patienten in Sachsen","Treatment practice of patients with Parkinson\u2019s disease in Saxony"],"prefix":"10.1007","volume":"93","author":[{"given":"Patrick","family":"Timpel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falko","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Themann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Hentschker-Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Falkenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"1273_CR1","volume-title":"Kerndaten der AOK PLUS","author":"AOK PLUS \u2013 Die Gesundheitskasse F\u00fcr Sachsen Und Th\u00fcringen \u2013 Gb Presse\/\u00d6ffentlichkeitsarbeit","year":"2021","unstructured":"AOK PLUS\u00a0\u2013 Die Gesundheitskasse F\u00fcr Sachsen Und Th\u00fcringen\u00a0\u2013 Gb Presse\/\u00d6ffentlichkeitsarbeit (2021) Strukturdaten der AOK PLUS. In: Kerndaten der AOK PLUS (Stand: 09\/2020)"},{"key":"1273_CR2","doi-asserted-by":"publisher","first-page":"e97073","DOI":"10.1371\/journal.pone.0097073","volume":"9","author":"P Benzinger","year":"2014","unstructured":"Benzinger\u00a0P, Rapp\u00a0K, Maetzler\u00a0W et\u00a0al (2014) Risk for femoral fractures in Parkinson\u2019s disease patients with and without severe functional impairment. Plos One 9:e97073\u2013e97073","journal-title":"Plos One"},{"key":"1273_CR3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1055\/a-0624-1671","volume":"45","author":"S Binder","year":"2018","unstructured":"Binder\u00a0S, Groppa\u00a0S, Woitalla\u00a0D et\u00a0al (2018) Patientenperspektive auf die Versorgungssituation im Krankheitsbild Morbus Parkinson in Deutschland \u2013 eine Querschnittserhebung. Akt Neurol 45:703\u2013713","journal-title":"Akt Neurol"},{"key":"1273_CR4","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/mds.26363","volume":"30","author":"BR Bloem","year":"2015","unstructured":"Bloem\u00a0BR, De Vries\u00a0NM, Ebersbach\u00a0G (2015) Nonpharmacological treatments for patients with Parkinson\u2019s disease. Mov Disord 30:1504\u20131520","journal-title":"Mov Disord"},{"issue":"3","key":"1273_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/ene.14627","volume":"28","author":"BR Bloem","year":"2021","unstructured":"Bloem\u00a0BR, Eimers\u00a0M, Van Galen\u00a0MS et\u00a0al (2021) From trials to clinical practice: temporal trends in the coverage of specialized allied health services for parkinson\u2019s disease. Eur J Neurol 28(3):775\u2013782","journal-title":"Eur J Neurol"},{"key":"1273_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1474-4422(20)30064-8","volume":"19","author":"BR Bloem","year":"2020","unstructured":"Bloem\u00a0BR, Henderson\u00a0EJ, Dorsey\u00a0ER et al (2020) Integrated and patient-centred management of Parkinson\u2019s disease: a\u00a0network model for reshaping chronic neurological care. Lancet Neurol 19:623\u2013634","journal-title":"Lancet Neurol"},{"key":"1273_CR7","doi-asserted-by":"publisher","first-page":"g1838","DOI":"10.1136\/bmj.g1838","volume":"348","author":"BR Bloem","year":"2014","unstructured":"Bloem\u00a0BR, Munneke\u00a0M (2014) Revolutionising management of chronic disease: the ParkinsonNet approach. BMJ 348:g1838","journal-title":"BMJ"},{"key":"1273_CR8","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie: Idiopathisches Parkinson-Syndrom. In: Entwicklungsstufe: S3. ARN 030\u2013010","author":"Deutsche Gesellschaft F\u00fcr Neurologie (Dgn)","year":"2016","unstructured":"Deutsche Gesellschaft F\u00fcr Neurologie (Dgn) (2016) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie: Idiopathisches Parkinson-Syndrom. In: Entwicklungsstufe: S3. ARN 030\u2013010"},{"key":"1273_CR9","first-page":"S3","volume":"8","author":"E Dorsey","year":"2018","unstructured":"Dorsey\u00a0E, Sherer\u00a0T, Okun\u00a0MS et\u00a0al (2018) The emerging evidence of the Parkinson pandemic. J\u00a0Park Dis 8:S3\u2013S8","journal-title":"J Park Dis"},{"key":"1273_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1212\/01.wnl.0000341769.50075.bb","volume":"72","author":"JA Driver","year":"2009","unstructured":"Driver\u00a0JA, Logroscino\u00a0G, Gaziano\u00a0JM et\u00a0al (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72:432\u2013438","journal-title":"Neurology"},{"key":"1273_CR11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"Gbd Parkinson\u2019s Disease Collaborators","year":"2018","unstructured":"Gbd Parkinson\u2019s Disease Collaborators (2018) Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a\u00a0systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:939\u2013953","journal-title":"Lancet Neurol"},{"key":"1273_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000266286","volume":"46","author":"L Hartelius","year":"1994","unstructured":"Hartelius\u00a0L, Svensson\u00a0P (1994) Speech and swallowing symptoms associated with parkinson\u2019s disease and multiple sclerosis: a survey. Folia Phoniatr Logop 46:9\u201317","journal-title":"Folia Phoniatr Logop"},{"key":"1273_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00500","author":"S Heinzel","year":"2018","unstructured":"Heinzel\u00a0S, Berg\u00a0D, Binder\u00a0S et\u00a0al (2018) Do we need to rethink the epidemiology and Healthcare utilization of parkinson\u2019s disease in Germany? Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2018.00500","journal-title":"Front Neurol"},{"key":"1273_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3233\/JPD-171100","volume":"7","author":"S Heinzel","year":"2017","unstructured":"Heinzel\u00a0S, Lerche\u00a0S, Maetzler\u00a0W et\u00a0al (2017) Global, yet incomplete overview of cohort studies in parkinson\u2019s disease. J\u00a0Parkinsons Dis 7:423\u2013432","journal-title":"J Parkinsons Dis"},{"key":"1273_CR15","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.parkreldis.2012.04.026","volume":"18","author":"DE Hobson","year":"2012","unstructured":"Hobson\u00a0DE, Lix\u00a0LM, Azimaee\u00a0M et al (2012) Healthcare utilization in patients with parkinson\u2019s disease: a population-based analysis. Park Relat Disord 18:930\u2013935","journal-title":"Park Relat Disord"},{"key":"1273_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/mds.26862","volume":"32","author":"J Isotalo","year":"2017","unstructured":"Isotalo\u00a0J, Vahlberg\u00a0T, Kaasinen\u00a0V (2017) Unchanged long-term rural-to-urban incidence ratio of Parkinson\u2019s disease. Mov Disord 32:474\u2013475","journal-title":"Mov Disord"},{"key":"1273_CR17","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.3390\/jcm9092906","volume":"9","author":"KF Loewenbr\u00fcck","year":"2020","unstructured":"Loewenbr\u00fcck\u00a0KF, Stein\u00a0DB, Amelung\u00a0VE et\u00a0al (2020) Parkinson network eastern saxony (PANOS): reaching consensus for a\u00a0regional Intersectoral integrated care concept for patients with parkinson\u2019s disease in the region of eastern saxony, Germany. J\u00a0Clin Med 9:2906","journal-title":"J Clin Med"},{"key":"1273_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jocn.2012.05.015","volume":"20","author":"M Lubomski","year":"2013","unstructured":"Lubomski\u00a0M, Rushworth\u00a0LR, Lee\u00a0W et al (2013) A cross-sectional study of clinical management, and provision of health services and their utilisation, by patients with Parkinson\u2019s disease in urban and regional Victoria. J\u00a0Clin Neurosci 20:102\u2013106","journal-title":"J Clin Neurosci"},{"key":"1273_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-017-0904-4","volume":"17","author":"G Mclean","year":"2017","unstructured":"Mclean\u00a0G, Hindle\u00a0JV, Guthrie\u00a0B et al (2017) Co-morbidity and polypharmacy in Parkinson\u2019s disease: insights from a\u00a0large Scottish primary care database. BMC Neurol 17:126\u2013126","journal-title":"BMC Neurol"},{"key":"1273_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/ane.12694","volume":"136","author":"M Nerius","year":"2017","unstructured":"Nerius\u00a0M, Fink\u00a0A, Doblhammer\u00a0G (2017) Parkinson\u2019s disease in Germany: prevalence and incidence based on health claims data. Acta Neurol Scand 136:386\u2013392","journal-title":"Acta Neurol Scand"},{"key":"1273_CR21","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3390\/jcm9051455","volume":"9","author":"T Prell","year":"2020","unstructured":"Prell\u00a0T, Siebecker\u00a0F, Lorrain\u00a0M et\u00a0al (2020) Recommendations for standards of network care for patients with parkinson\u2019s disease in Germany. J\u00a0Clin Med 9:1455","journal-title":"J Clin Med"},{"key":"1273_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/14737175.2019.1561285","volume":"19","author":"DLM Radder","year":"2019","unstructured":"Radder\u00a0DLM, De Vries\u00a0NM, Riksen\u00a0NP et\u00a0al (2019) Multidisciplinary care for people with Parkinson\u2019s disease: the new kids on the block! Expert Rev Neurother 19:145\u2013157","journal-title":"Expert Rev Neurother"},{"key":"1273_CR23","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/gps.4414","volume":"31","author":"O Riedel","year":"2016","unstructured":"Riedel\u00a0O, Bitters\u00a0D, Amann\u00a0U et\u00a0al (2016) Estimating the prevalence of Parkinson\u2019s disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data. Int J Geriatr Psychiatry 31:938\u2013943","journal-title":"Int J Geriatr Psychiatry"},{"key":"1273_CR24","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1503\/cmaj.151179","volume":"188","author":"P Rizek","year":"2016","unstructured":"Rizek\u00a0P, Kumar\u00a0N, Jog\u00a0MS (2016) An update on the diagnosis and treatment of Parkinson disease. CMAJ 188:1157\u20131165","journal-title":"CMAJ"},{"key":"1273_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/mds.27063","volume":"33","author":"A Rossi","year":"2018","unstructured":"Rossi\u00a0A, Berger\u00a0K, Chen\u00a0H et\u00a0al (2018) Projection of the prevalence of parkinson\u2019s disease in the coming decades: revisited. Mov Disord 33:156\u2013159","journal-title":"Mov Disord"},{"key":"1273_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00115-020-00890-4","volume":"91","author":"S Stangl","year":"2020","unstructured":"Stangl\u00a0S, Haas\u00a0K, Eggers\u00a0C et al (2020) Versorgung von Parkinson-Patienten in Deutschland. Nervenarzt 91:493\u2013502","journal-title":"Nervenarzt"},{"key":"1273_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12883-017-0985-0","volume":"17","author":"A Tanguy","year":"2017","unstructured":"Tanguy\u00a0A, J\u00f6nsson\u00a0L, Ishihara\u00a0L (2017) Inventory of real world data sources in Parkinson\u2019s disease. BMC Neurol 17:213","journal-title":"BMC Neurol"},{"key":"1273_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092787","author":"J Tennigkeit","year":"2020","unstructured":"Tennigkeit\u00a0J, Feige\u00a0T, Haak\u00a0M et\u00a0al (2020) Structured care and self-management education for persons with parkinson\u2019s disease: why the first does not go without the second\u2014systematic review, experiences and implementation concepts from Sweden and Germany. J\u00a0Clin Med. https:\/\/doi.org\/10.3390\/jcm9092787","journal-title":"J Clin Med"},{"key":"1273_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00115-018-0590-5","volume":"90","author":"L T\u00f6nges","year":"2019","unstructured":"T\u00f6nges\u00a0L, Bartig\u00a0D, Muhlack\u00a0S et al (2019) Charakteristika und Dynamik der station\u00e4ren Behandlung von Parkinson-Patienten in Deutschland. Nervenarzt 90:167\u2013174","journal-title":"Nervenarzt"},{"key":"1273_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1023\/A:1011807919632","volume":"23","author":"DA Van De Vijver","year":"2001","unstructured":"Van De Vijver\u00a0DA, Stricker\u00a0BH, Breteler\u00a0MM et\u00a0al (2001) Evaluation of antiparkinsonian drugs in pharmacy records as a\u00a0marker for Parkinson\u2019s disease. Pharm World Sci 23:148\u2013152","journal-title":"Pharm World Sci"},{"issue":"Suppl 1","key":"1273_CR31","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s10654-011-9581-6","volume":"26","author":"K Wirdefeldt","year":"2011","unstructured":"Wirdefeldt\u00a0K, Adami\u00a0HO, Cole\u00a0P et\u00a0al (2011) Epidemiology and etiology of parkinson\u2019s disease: a\u00a0review of the evidence. Eur J Epidemiol 26(Suppl 1):S1\u2013S58","journal-title":"Eur J Epidemiol"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-022-01273-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-022-01273-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-022-01273-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T13:05:50Z","timestamp":1669986350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-022-01273-7"}},"subtitle":["Eine sekund\u00e4rdatenbasierte Analyse der Inanspruchnahme im Beobachtungszeitraum 2011 bis 2019","A secondary data-based analysis of utilization in the observation period 2011\u20132019"],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1273"],"URL":"https:\/\/doi.org\/10.1007\/s00115-022-01273-7","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"assertion":[{"value":"24 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0Falkenburger hat ohne Bezug zur vorgestellten Studie Vortrags- und Beraterhonorare von Desitin und UCB Pharma erhalten. Es besteht im Hinblick auf diese Publikation kein Interessenkonflikt. J.\u00a0Schmitt hat ohne Bezug zur vorgestellten Studie institutionelle Unterst\u00fctzung f\u00fcr wissenschaftlich initiierte Forschungsprojekte von Pfizer, ALK, Novartis und Sanofi erhalten und war als Berater f\u00fcr Lilly, Sanofi und ALK t\u00e4tig. M.\u00a0Wolz hat ohne Bezug zur vorgestellten Studie Vortrags- und Beraterhonorare von Zambon, Valeant, Desitin, TEVA, UCB Pharma, Abbvie, Bial, Licher und Daiichi Sankyo erhalten. Es besteht im Hinblick auf diese Publikation kein Interessenkonflikt. P.\u00a0Timpel, F.\u00a0Tesch, G.\u00a0M\u00fcller, C.\u00a0Lang, P.\u00a0Themann und U.\u00a0Hentschker-Ottgeben geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}